Publications by authors named "Christopher Molineaux"

Claim this Profile
A
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Melissa Alsina, Suzanne Trudel, Richard R Furman, Peter J Rosen, Owen A O'Connor, Christopher J Molineaux

Clin Cancer Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
Jinfu Yang, Zhengping Wang, Ying Fang, Jing Jiang, Frances Zhao, Christopher J Molineaux

Drug Metab Dispos· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
Owen A O'Connor, A Keith Stewart, Marcy Vallone, Christopher J Molineaux, Lori A Kunkel

Clin Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Susan D Demo, Christopher J Kirk, Monette A Aujay, Tonia J Buchholz, Maya Dajee, Christopher J Molineaux

Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy.
Richard E Gilbert, Aysel Akdeniz, Stephen Weitz, William R Usinger, Christopher Molineaux

Diabetes Care· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis